RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease

Repligen

Status and phase: Terminated; Phase 1

Conditions: Mitochondrial Diseases

Treatments: Drug: RG2133 (2',3',5'-tri-O-acetyluridine)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00060515

RG2133-01

Details and patient eligibility

About

The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.

Sex: All

Ages: 3+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Mitochondrial Disease